In addition, as a manifestation of severe CRS or as its pathophysiological consequence, the occurrence of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) has been reported in patients treated with CAR.CD192,3 or CAR.CD22-T cells4. This evidence concerns the gene CCR2 and hemophagocytic syndrome.